ESMO 2014: breast cancer drug shows “unprecedented” survival rates
Results have been presented on a new treatment for an aggressive breast cancer form at the annual congress of the European Society for Medical Oncology (ESMO). Definitive results of the CLEOPATRA study show a median overall survival of over fifteen months. That is promising news for patients suffering from this aggressive form of cancer, that accounts for nearly a quarter of all breast cancers. Continue reading